Anbenitamab clinical trials
Also written KN026.
How each study uses anbenitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anbenitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 3
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (6) · Shanghai JMT-Bio Inc. (4) · Peking University (2) · Peking University Cancer Hospital & Institute (1)
Often tested with
Tested in the same studies.
Docetaxel (2) · Erfonrilimab (2) · Enlonstobart (2) · Concurrent Chemotherapy (1) · Anbenitamab repodatecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test anbenitamab, phase 3 first.
- Dec 2026A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerPhase 3 · Shanghai JMT-Bio Inc.
- Dec 2026KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaPhase 2 · Peking University Cancer Hospital & Institute
Studies
Open first, then newest update. How each study uses anbenitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460Written as KN026
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT07332533Written as KN026
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06998771Written as KN026
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as KN026
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as KN026
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingPhase 3Shanghai JMT-Bio Inc.NCT06747338Written as KN026
- KN026 Combined With KN046 in Subjects With HER2 Positive Solid TumorCompletedPhase 1Peking UniversityNCT04040699Written as KN026 combined with KN046
- KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction CancerCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03925974Written as KN026 10 mg/kg QW
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric CancerCompletedPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03619681Written as KN026
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerActive, not recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04165993Written as Concurrent chemotherapy and KN026
- Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04521179Written as KN026 combination
- Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast CancerStatus unknownPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04881929Written as KN026
- KN026 in Patients With HER2 Expressing Breast Cancer and Gastric CancerStatus unknownPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03847168Written as KN026
Given beside what is tested · 1 — anbenitamab is usual care or a partner of the new treatment
Codes
What other systems call anbenitamab · ClinicalTrials.gg INT017798
- UNII (FDA) RHS90QRF9EANBENITAMABOne source FDA
- NCI Thesaurus C162577AnbenitamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RHS90QRF9E | ANBENITAMAB | One source FDA |
| NCI Thesaurus | C162577 | Anbenitamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.